Journal: Molecular Medicine Reports

Article Title: CYP2J2 participates in atherogenesis by mediating cell proliferation, migration and foam cell formation

doi: 10.3892/mmr.2016.6039

Figure Lengend Snippet: CYP2J2 is successfully overexpressed in HUVECs, HASMCs, and foam cells infected with LV-CYP2J2. (A) HUVEC, (B) HASMC and (C) foam cells were successfully infected with LV-CYP2J2-GFP or LV-GFP at MOI=100. Reverse transcription-quantitative polymerase chain reaction revealed that CYP2J2 was overexpressed in (D) HUVECs, (E) HASMCs and (F) foam cells. Western blot analysis verified that CYP2J2 was overexpressed in (G) HUVECs, (H) HAMSCs and (I) foam cells. CYP2J2, cytochrome P450 family 2 subfamily J polypeptide 2; HUVECs, human umbilical vein endothelial cells; HASMCs, human arterial smooth muscle cells; LV, lentivirus; GFP, green fluorescent protein. **P<0.01 vs. LV-GFP group.

Article Snippet: The membranes were then blocked with 5% milk in Tris-buffered saline containing 0.05% Tween-20 (TBST) for 1 h at 37°C, incubated for 1 h with anti-CYP2J2 mouse monoclonal primary antibody (1:500; cat. no. CF503636, OriGene Technologies, Inc., Beijing, China), washed three times with TBST, and further incubated with rabbit anti-mouse IgG (H+L)-horseradish peroxidase (HRP) conjugated secondary antibody (1:5,000; cat. no. 6170–05, SouthernBiotech, Birmingham, AL, USA) for 40 min.

Techniques: Infection, Reverse Transcription, Real-time Polymerase Chain Reaction, Western Blot

Journal: Molecular Medicine Reports

Article Title: CYP2J2 participates in atherogenesis by mediating cell proliferation, migration and foam cell formation

doi: 10.3892/mmr.2016.6039

Figure Lengend Snippet: CYP2J2 overexpression promotes HUVEC and suppresses HASMC proliferation. Following infection for 72 h with LV-CYP2J2-GFP or LV-GFP, cells were harvested for cell proliferation assays. Absorbance at a wavelength of 490 nm was measured at 12, 24, 48, and 72 h time-points for (A) HUVECs and (B) HASMCs. Data are expressed as the mean ± standard deviation. *P<0.05, **P<0.01 vs. LV-GFP. CYP2J2, cytochrome P450 family 2 subfamily J polypeptide 2; HUVECs, human umbilical vein endothelial cells; HASMCs, human arterial smooth muscle cells; LV, lentivirus; GFP, green fluorescent protein.

Article Snippet: The membranes were then blocked with 5% milk in Tris-buffered saline containing 0.05% Tween-20 (TBST) for 1 h at 37°C, incubated for 1 h with anti-CYP2J2 mouse monoclonal primary antibody (1:500; cat. no. CF503636, OriGene Technologies, Inc., Beijing, China), washed three times with TBST, and further incubated with rabbit anti-mouse IgG (H+L)-horseradish peroxidase (HRP) conjugated secondary antibody (1:5,000; cat. no. 6170–05, SouthernBiotech, Birmingham, AL, USA) for 40 min.

Techniques: Over Expression, Infection, Standard Deviation

Journal: Molecular Medicine Reports

Article Title: CYP2J2 participates in atherogenesis by mediating cell proliferation, migration and foam cell formation

doi: 10.3892/mmr.2016.6039

Figure Lengend Snippet: CYP2J2 overexpression promotes HUVEC migration and inhibits HASMC migration. (A) Representative images of crystal violet-stained HUVECs (magnification, ×200) and (B) average numbers of migrating HUVECs per field for the experimental groups. (C) Representative images of crystal violet-stained HASMC (magnification, ×200) and (D) average numbers of migrating HAMSCs per field for the experimental groups. The data are presented as the mean ± standard deviation. **P<0.01 vs. LV-GFP. CYP2J2, cytochrome P450 family 2 subfamily J polypeptide 2; HUVECs, human umbilical vein endothelial cells; HASMCs, human arterial smooth muscle cells; LV, lentivirus; GFP, green fluorescent protein.

Article Snippet: The membranes were then blocked with 5% milk in Tris-buffered saline containing 0.05% Tween-20 (TBST) for 1 h at 37°C, incubated for 1 h with anti-CYP2J2 mouse monoclonal primary antibody (1:500; cat. no. CF503636, OriGene Technologies, Inc., Beijing, China), washed three times with TBST, and further incubated with rabbit anti-mouse IgG (H+L)-horseradish peroxidase (HRP) conjugated secondary antibody (1:5,000; cat. no. 6170–05, SouthernBiotech, Birmingham, AL, USA) for 40 min.

Techniques: Over Expression, Migration, Staining, Standard Deviation

Journal: Molecular Medicine Reports

Article Title: CYP2J2 participates in atherogenesis by mediating cell proliferation, migration and foam cell formation

doi: 10.3892/mmr.2016.6039

Figure Lengend Snippet: CYP2J2 overexpression suppresses oxidized low density lipoprotein-induced foam cell formation. (A) Oil Red O staining was used to detect alterations in cellular lipid accumulation following infection with LV-GFP or LV-CYP2J2-GFP. Magnification ×200. (B) Total and (C) free cholesterol in culture medium were determined using a quantitation kit. Data are presented as the mean ± standard deviation. **P<0.01 vs. LV-GFP. CYP2J2, cytochrome P450 family 2 subfamily J polypeptide 2; LV, lentivirus; GFP, green fluorescent protein.

Article Snippet: The membranes were then blocked with 5% milk in Tris-buffered saline containing 0.05% Tween-20 (TBST) for 1 h at 37°C, incubated for 1 h with anti-CYP2J2 mouse monoclonal primary antibody (1:500; cat. no. CF503636, OriGene Technologies, Inc., Beijing, China), washed three times with TBST, and further incubated with rabbit anti-mouse IgG (H+L)-horseradish peroxidase (HRP) conjugated secondary antibody (1:5,000; cat. no. 6170–05, SouthernBiotech, Birmingham, AL, USA) for 40 min.

Techniques: Over Expression, Staining, Infection, Quantitation Assay, Standard Deviation

Journal: British Journal of Pharmacology

Article Title: Antagonizing midkine accelerates fracture healing in mice by enhanced bone formation in the fracture callus

doi: 10.1111/bph.13503

Figure Lengend Snippet: Mdk serum levels (pg·mL −1 ) during fracture healing in 9‐month‐old mice

Article Snippet: The Mdk‐Ab (mouse anti‐human Mdk IgG1 monoclonal antibody, cross reactive to murine Mdk; elisa EC 50 to human Mdk: 31.7 ng·mL −1 ; and elisa EC 50 to mouse Mdk: 37.8 ng·mL −1 , provided by Cellmid Ltd., Sydney, Australia) was administered s.c. at 25 mg·kg −1 twice weekly for 3 weeks; this treatment was initiated immediately post‐operatively to the animals of group 1.

Techniques: